-Frank J Gonzalez Researcher Activity Profile

Research Author Detailed Information 

Frank J Gonzalez Publication Rate By Year

Frank J Gonzalez has published 1 paper(s) in 1990, 2 paper(s) in 2006, 39 paper(s) in 2007, 17 paper(s) in 2008, for a total of 59 research publications in total.

Frank J Fj Gonzalez Author Information

LAST NAME: gonzalez

FIRST NAME: Frank J

INITIALS: fj

AFFILIATION:

Papers

Frank J Gonzalez's Publication Record

1. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Year Published: 2007
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
2. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio. Year Published: 2006
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
3. Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha. Year Published: 2006
Department of Pharmacology and Toxicology, University of Kansas, Lawrence, Kansas 66045, USA.
4. The PREgnane X receptor gene-humanized mouse: a model for investigating drug-drug interactions mediated by cytochromes P450 3A. Year Published: 2007
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
5. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. Year Published: 2007
Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.
6. A comprehensive investigation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) metabolism in the mouse using a multivariate data analysis approach. Year Published: 2007
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
7. Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Year Published: 2007
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 37, Room 3106, Bethesda, MD 20892, USA.
8. CCAAT/enhancer-binding protein delta (C/EBPdelta) maintains amelogenin expression in the absence of C/EBPalpha in vivo. Year Published: 2007
The Center for Craniofacial Molecular Biology, University of Southern California, Los Angeles, California 90033, USA.
9. Critical role for transcription coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein/TRAP220 in liver regeneration and PPARalpha ligand-induced liver tumor development. Year Published: 2007
Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611-3008, USA.
10. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. Year Published: 2007
Department of Medicine, Division of Endocrinology and Metabolism, UCSD, La Jolla, California, USA. ahevener@mednet.ucla.edu
11. Role of CYP3A and CYP2E1 in alcohol-mediated increases in acetaminophen hepatotoxicity: comparison of wild-type and Cyp2e1(-/-) mice. Year Published: 2007
Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire, USA.
12. Metabolomic and genetic analysis of biomarkers for peroxisome proliferator-activated receptor alpha expression and activation. Year Published: 2007
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
13. PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism. Year Published: 2007
Department of Veterinary and Biomedical Sciences , The Pennsylvania State University, 312 Life Sciences Building, University Park, Pennsylvania 16802, USA.
14. Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients. Year Published: 2007
Medical Oncology Service, Virgen de la Victoria University Hospital, E-29010 Malaga, Spain.
15. CCAAT/enhancer-binding protein delta (C/EBPdelta) maintains amelogenin expression in the absence of C/EBPalpha in vivo. Year Published: 2007
The Center for Craniofacial Molecular Biology, University of Southern California, Los Angeles, California 90033, USA.
16. ME3738 protects against lithocholic acid-induced hepatotoxicity, which is associated with enhancement of biliary bile acid and cholesterol output. Year Published: 2007
Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Aramaki, Aoba-ku, Sendai 980-8578, Japan.
17. Differential effects of aging, drinking and exercise on serum cholesterol levels dependent on the PPARA-V227A polymorphism. Year Published: 2007
Department of Occupational and Environmental Health, Nagoya University Graduate School of Medicine, Japan.
18. Metabolomics. Year Published: 2007
Institute of Pharmacology, 1st Faculty of Medicine, Charles University, 128 00 Praha 2, Czech Republic. jidle@lf1.cuni.cz
19. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Year Published: 2007
Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA.
20. Infrared imager requirements for breast cancer detection. Year Published: 2007
21. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. Year Published: 2007
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
22. Regulation of tissue-specific expression of the human and mouse urate transporter 1 gene by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. Year Published: 2007
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
23. PPARalpha protects proximal tubular cells from acute fatty acid toxicity. Year Published: 2007
Department of Metabolic Regulation, Institute on Aging and Adaptation, Shinshu University School of Medicine, Matsumoto, Japan. yujibeat@hsp.md.shinshu-u.ac.jp
24. Purification and characterization of four catalytically active testosterone 6 beta-hydroxylase P-450s from rat liver microsomes: comparison of a novel form with three structurally and functionally related forms. Year Published: 1990
Department of Pharmacology, School of Medicine, Keio University, Tokyo.
25. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Year Published: 2007
Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA.
26. Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Year Published: 2007
Department of Pathology, Osaka City University Medical School, Osaka, Japan.
27. Peroxisome proliferator-activated receptor- /{delta} (PPAR /{delta}) ligands do not potentiate growth of human cancer cell lines. Year Published: 2007
Department of Veterinary and Biomedical Sciences and the Center of Molecular Toxicology and Carcinogenesis.
28. The PPAR{alpha}-Humanized Mouse: A Model to Investigate Species Differences in Liver Toxicity Mediated by PPAR{alpha}. Year Published: 2007
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892.
29. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines. Year Published: 2007
Department of Veterinary and Biomedical Sciences and the Center of Molecular Toxicology and Carcinogenesis, Pennsylvania State University, University Park, PA 16802, USA.
30. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Year Published: 2007
Department of Veterinary and Biomedical Sciences and The Center of Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802, USA.
31. LC-MS-based metabolomics in drug metabolism. Year Published: 2007
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
32. PPARalpha protects proximal tubular cells from acute fatty acid toxicity. Year Published: 2007
Department of Metabolic Regulation, Institute on Aging and Adaptation, Shinshu University School of Medicine, Matsumoto, Japan. yujibeat@hsp.md.shinshu-u.ac.jp
33. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Year Published: 2008
Department of Veterinary and Biomedical Sciences and The Center for Molecular Toxicology and Carcinogenesis, The Huck Institute of Life Sciences, The Pennsylvania State University, University Park, PA.
34. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice. Year Published: 2008
Department of Veterinary and Biomedical Sciences and The Center for Molecular Toxicology and Carcinogenesis, The Huck Institute of Life Sciences, The Pennsylvania State University, University Park, PA 16802, USA.
35. Regulation of tissue-specific expression of the human and mouse urate transporter 1 gene by hepatocyte nuclear factor 1 alpha/beta and DNA methylation. Year Published: 2007
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
36. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. Year Published: 2007
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
37. The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Year Published: 2007
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
38. ME3738 protects against lithocholic acid-induced hepatotoxicity, which is associated with enhancement of biliary bile acid and cholesterol output. Year Published: 2007
Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Aramaki, Aoba-ku, Sendai 980-8578, Japan.
39. Association between VEGF expression in tumour-associated macrophages and elevated serum VEGF levels in primary colorectal cancer patients. Year Published: 2007
Medical Oncology Service, Virgen de Victoria University Hospital, E-29010 Malaga, Spain. fjgonzalez02@yahoo.es
40. Differential effects of aging, drinking and exercise on serum cholesterol levels dependent on the PPARA-V227A polymorphism. Year Published: 2007
Department of Occupational and Environmental Health, Nagoya University Graduate School of Medicine, Japan.
41. Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis in vivo. Year Published: 2007
Department of Pathology, Osaka City University Medical School, Osaka, Japan.
42. Cytochrome P450 Expression and Regulation in CYP3A4/CYP2D6 Double Transgenic Humanized Mice. Year Published: 2008
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14260. aimingyu@buffalo.edu.
43. Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. Year Published: 2008
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
44. Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1 alpha/beta. Year Published: 2008
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, USA.
45. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Year Published: 2008
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
46. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Year Published: 2008
Department of Veterinary and Biomedical Sciences and The Center of Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802, USA.
47. Basal and inducible CYP1 mRNA quantitation and protein localization throughout the mouse gastrointestinal tract. Year Published: 2008
Department of Environmental Health, and The Center for Environmental Genetics (CEG), University of Cincinnati Medical Center, Cincinnati, OH 45267-0056, USA.
48. Metabolomics Reveals that Hepatic Stearoyl-CoA Desaturase 1 Downregulation Exacerbates Inflammation and Acute Colitis. Year Published: 2008
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
49. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Year Published: 2007
Department of Veterinary and Biomedical Sciences and The Center of Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802, USA.
50. Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. Year Published: 2008
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
51. Transcriptional regulation of human and mouse organic anion transporter 1 by hepatocyte nuclear factor 1 alpha/beta. Year Published: 2008
Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, USA.
52. Identification of Novel Toxicity-associated Metabolites by Metabolomics and Mass Isotopomer Analysis of Acetaminophen Metabolism in Wild-type and Cyp2e1-null Mice. Year Published: 2008
Laboratory of Metabolism, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892.
53. The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha. Year Published: 2007
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
54. Cytochrome P450 expression and regulation in CYP3A4/CYP2D6 double transgenic humanized mice. Year Published: 2008
Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY 14260, USA.
55. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. Year Published: 2007
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
56. A metabolomic perspective of melatonin metabolism in the mouse. Year Published: 2008
Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, Building 37, Room 3106, Bethesda, Maryland 20892. fjgonz@helix.nih.gov.
57. Role of CYP1B1 in glaucoma. Year Published: 2008
Molecular Toxicology & Environmental Health Sciences Program, Department of Pharmaceutical Sciences, University of Colorado Health Sciences Center, Denver, CO 80262, USA. vasilis.vasiliou@uchsc.edu
58. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. Year Published: 2008
Department of Metabolic Regulation, Institute on Aging and Adaptation, Shinshu University Graduate School of Medicine, Matsumoto, Nagano, Japan. naopi@hsp.md.shinshu-u.ac.jp
59. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Year Published: 2008
Department of Veterinary and Biomedical Sciences and The Center of Molecular Toxicology and Carcinogenesis, The Pennsylvania State University, University Park, PA 16802, USA.